 | |
| Clinical data | |
|---|---|
| Trade names | Nailin |
| Other names | BMS-379224; BFE-1224; E-1224 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H20F2N5O5PS |
| Molar mass | 547.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fosravuconazole (trade nameNailin) is atriazole antifungal agent.[1][2] In Japan, it is approved for the treatment ofonychomycosis, a fungal infection of the nail.[3] It is aprodrug that is converted intoravuconazole.[1]
Drugs for Neglected Diseases Initiative (DNDi) and the Japanese pharmaceutical companyEisai found that fosravuconazole works as a treatment formycetoma, a serious condition.[1][4][5] The Phase II clinical trial found that oral fosravuconazole was safe, patient-friendly, and effective in treating eumycetoma.[6][7] Eumycetoma mainly affects young adults in poorer, rural areas; the standard treatment isitraconazole, which is much more expensive at aboutUS$2,000 for a year than fosravuconazole and unaffordable, and not available in all endemic countries.[7]
The head of mycetoma at the DNDi labelled the discovery 'momentous', and said 'We were all very excited, it's going to be a gamechanger'.
